Spnib 100 mg Dasatinib Tablets (1 bottle / 30 tabs)

Buy Spnib 100 mg Dasatinib Tablets Online

Spnib 100 mg Dasatinib Tablets (1 bottle / 30 tabs)

At a Glance

Generic Name: Dasatinib

Brand Name: Spnib 100 mg

Strength & Pack Size: 100 mg tablets, 1 bottle / 30 tablets

Dosage Form & Route: Oral film-coated tablets for swallowing whole with water

Therapeutic Class: Second-generation BCR-ABL tyrosine kinase inhibitor and SRC family kinase inhibitor

Primary Indications: Philadelphia chromosome–positive chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL), according to local label

Typical Use in Therapy: Used as first- or subsequent-line TKI option in Ph+ CML or Ph+ ALL under specialist protocols

Mode of Action: Inhibits BCR-ABL and other kinases to block abnormal signalling and leukemic cell proliferation

Key Benefits: Active in many patients resistant or intolerant to imatinib, with rapid and deep molecular responses in appropriately selected cases

Precautions: Myelosuppression, bleeding, fluid retention, pulmonary arterial hypertension and QT prolongation require close monitoring

Storage: Store below 25 °C in the original container, tightly closed and protected from moisture

Product Description

Spnib 100 mg contains dasatinib, an oral second-generation tyrosine kinase inhibitor used in the treatment of Philadelphia chromosome–positive leukemias. It is typically prescribed for Ph+ chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) in adults when a potent BCR-ABL inhibitor is needed, including situations where imatinib has failed due to resistance or intolerance, or where local protocols support dasatinib in earlier lines of therapy.

Each bottle of Spnib 100 mg supplied by Generic Meds Mart contains 30 film-coated dasatinib tablets. The 100 mg strength is commonly used in adult regimens, although the exact dose and schedule are always determined by a hematologist or oncologist based on disease phase, prior treatment, concomitant medicines and the patient’s overall health. Spnib 100 mg dasatinib tablets are taken by mouth, usually once daily, and are intended for long-term use as part of a continuous tyrosine kinase inhibitor strategy for Ph+ CML or Ph+ ALL where clinically appropriate.

Generic Meds Mart works only with licensed manufacturers and authorised distributors for oncology TKIs like Spnib 100 mg. Bottles are supplied in original, sealed packaging so that treating centres can verify brand, strength, batch number and expiry before dispensing. Outer shipping cartons are neutral, without visible references to leukemia or dasatinib, helping to protect patient privacy during international delivery. Prices are displayed in USD to make long-term therapy planning more transparent for patients and clinics.

Key Uses

Spnib 100 mg dasatinib tablets are used for guideline-based indications in Philadelphia chromosome–positive leukemias, according to local product information and specialist recommendations. In clinical practice, this typically includes:

Spnib 100 mg as a second-generation BCR-ABL inhibitor in adults with Ph+ CML, including chronic, accelerated or blast phase disease where dasatinib is considered appropriate by the treating team.

Spnib 100 mg in adults with Ph+ ALL when a potent oral TKI is required in induction, consolidation or maintenance phases alongside multi-agent chemotherapy or other targeted regimens, based on protocol.

Depending on region and label, dasatinib may be used either after imatinib failure or intolerance, or as a first-line option in selected patients. The decision to use Spnib 100 mg, and its position relative to other TKIs such as imatinib or nilotinib, must always be made by an experienced hematologist working within evidence-based guidelines.

How Dasatinib Works in Chemotherapy

Dasatinib, the active ingredient in Spnib 100 mg, is a potent inhibitor of the BCR-ABL tyrosine kinase, the abnormal fusion protein generated by the Philadelphia chromosome translocation t(9;22). This fusion kinase drives uncontrolled proliferation and survival of leukemic cells in Ph+ CML and Ph+ ALL.

By binding to and inhibiting BCR-ABL, dasatinib blocks downstream signalling pathways that support leukemic cell division and resistance to apoptosis. Dasatinib also inhibits other kinases, including members of the SRC family, which may contribute to its activity in leukemic cells. Compared with first-generation TKIs, dasatinib has broader binding characteristics and can retain activity against many imatinib-resistant BCR-ABL mutations, although some mutations remain problematic.

In clinical use, effective inhibition of BCR-ABL by Spnib 100 mg dasatinib tablets can lead to rapid reductions in leukocyte counts, improved bone marrow morphology and achievement of cytogenetic and molecular responses. Achieving and maintaining deep molecular responses is associated with better long-term outcomes in Ph+ CML and Ph+ ALL when managed according to specialist protocols.

Dosage & Administration

Spnib 100 mg must be prescribed and monitored by a hematologist or oncologist experienced in managing Ph+ leukemias. The usual adult dose and schedule are defined in the official product information and may vary according to indication, disease phase, prior therapies and local practice. Tablets are swallowed whole with water and should not be crushed or chewed.

Dasatinib can be taken with or without food, but patients should follow the exact instructions given by their treatment centre. Certain medicines, including proton pump inhibitors and strong CYP3A4 inhibitors or inducers, can affect dasatinib exposure and may need to be avoided or adjusted. Regular blood counts, liver function tests and clinical assessments are required to monitor response and toxicity. Dose interruptions, reductions or switches to an alternative TKI may be necessary in cases of significant myelosuppression, fluid retention, pulmonary events or other adverse effects. Patients should never change their Spnib 100 mg dose without specialist advice.

Precautions

Before starting Spnib 100 mg dasatinib tablets, the treatment team will review the patient’s medical history, ECG, cardiovascular status, liver and kidney function, concomitant medicines and bleeding risk. Dasatinib can cause myelosuppression, including neutropenia, thrombocytopenia and anemia, so frequent full blood count monitoring is essential, particularly in the first months of therapy.

Important precautions described in dasatinib prescribing information include risks of serious bleeding, fluid retention (such as pleural effusion and pericardial effusion), pulmonary arterial hypertension, QT interval prolongation and hepatotoxicity. Caution is required in patients with prior heart disease, uncontrolled hypertension, lung disease, liver impairment or those taking other QT-prolonging drugs. Women who are pregnant or may become pregnant should not handle dasatinib tablets without protection, and effective contraception is recommended for patients of reproductive potential.

Dasatinib Side Effects

Common side effects

Common dasatinib side effects in patients taking Spnib 100 mg include myelosuppression with low white cells, low platelets or anemia; headache; fatigue; nausea; vomiting; diarrhoea; abdominal discomfort; rash; musculoskeletal pain; mild fluid retention such as ankle swelling; and mild elevations in liver enzymes. Some patients experience cough or shortness of breath, which may be related to fluid around the lungs and must be assessed by the treating team.

These effects are often manageable with temporary treatment interruption, dose reduction, supportive therapy such as transfusions or growth factors and careful monitoring. Patients should attend all scheduled blood tests and clinic visits so that emerging issues can be detected early.

Serious side effects

Serious dasatinib adverse effects require urgent medical attention. These may include severe thrombocytopenia or neutropenia with increased risk of bleeding or infection; major haemorrhage; significant pleural or pericardial effusion; signs of pulmonary arterial hypertension such as progressive shortness of breath and fatigue; marked fluid overload; severe liver injury with jaundice; and serious cardiac events or marked QT prolongation.

Patients should contact emergency services or their treating centre immediately if they experience chest pain, severe shortness of breath, sudden swelling, black or bloody stools, coughing up blood, high fever, uncontrolled bleeding, confusion, severe dizziness or fainting. The treating team may need to interrupt Spnib 100 mg, adjust the dose or switch to an alternative therapy depending on the severity and type of adverse event.

Storage

Spnib 100 mg dasatinib tablets should be stored in the original, tightly closed bottle below 25 °C, protected from moisture and heat. The bottle should be kept out of the sight and reach of children and should not be stored in very humid environments such as bathrooms. Tablets must not be used after the expiry date shown on the label and carton. Unused or expired tablets should be returned to a pharmacy or disposed of in accordance with local oncology waste guidelines, not placed in household rubbish or wastewater.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to specialist oral oncology medicines such as Spnib 100 mg dasatinib tablets. We source only from licensed manufacturers and authorised distributors who comply with Good Manufacturing Practice and maintain traceable batch records. Each bottle of Spnib 100 mg is supplied in sealed, original packaging so pharmacists and clinicians can verify brand name, strength, batch number and expiry before dispensing to patients.

Orders placed through Generic Meds Mart are billed in USD, simplifying cost planning for long-term TKI therapy. Shipments are packed in neutral outer cartons with no explicit mention of leukemia, dasatinib or Spnib 100 mg, and where available, tracking information is provided so that patients and clinics can coordinate refills before existing supplies run out. Our support team can help with ordering and logistics questions, while all decisions about whether to use a specific tyrosine kinase inhibitor remain exclusively with your hematology or oncology team.

Order Now

Spnib 100 mg dasatinib tablets are a potent, targeted therapy for Philadelphia chromosome–positive leukemias and must not be started without a detailed plan from an experienced specialist. Before you buy Spnib 100 mg online from Generic Meds Mart, ensure that your diagnosis, BCR-ABL status, prior TKI exposure and overall treatment goals have been fully discussed with your hematologist. You should have clear instructions about your daily dose, timing, monitoring schedule and what to do if doses are missed or side effects occur.

Once your plan is in place, your team can calculate how many bottles of Spnib 100 mg (1 bottle / 30 tabs) are needed for the initial treatment period. You can then select the appropriate quantity on Generic Meds Mart, add it to your cart and complete secure checkout in USD. Your medicine will be shipped in discreet packaging with full product labelling. You should never change, pause or stop dasatinib therapy on your own; any new or severe symptoms must be discussed promptly with your specialist team, and emergency services should be contacted when serious warning signs appear.

FAQ about Spnib (Dasatinib)

Q1: What is Spnib 100 mg used for?
Spnib 100 mg contains dasatinib, a second-generation BCR-ABL tyrosine kinase inhibitor used under specialist supervision for Philadelphia chromosome–positive chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL), according to local approvals and guidelines.

Q2: How should I take Spnib 100 mg tablets?
Spnib 100 mg dasatinib tablets are usually taken once daily, swallowed whole with water. You should follow the exact dose and timing given by your hematologist and avoid crushing or chewing the tablets. If you miss a dose, follow the instructions in your product leaflet or contact your clinic rather than doubling up the next day.

Q3: Will I need regular blood tests while on dasatinib?
Yes. Dasatinib can cause myelosuppression and other laboratory changes, so regular full blood counts and chemistry tests are essential, especially early in treatment. Your team will use these results to adjust your dose, pause therapy or provide supportive care if necessary.

Q4: Can Spnib 100 mg interact with other medicines?
Dasatinib is metabolised by CYP3A4 and can interact with many medicines, including certain antifungals, antibiotics, antivirals, anticonvulsants and stomach acid–reducing drugs. You should provide a full list of all prescription, over-the-counter and herbal products to your specialist, and never start or stop any medicine without checking for potential interactions.

Q5: How long will I need to stay on Spnib 100 mg?
Treatment duration with Spnib 100 mg dasatinib tablets is highly individual. Many patients remain on therapy for years to maintain deep molecular responses, while others may switch TKIs or change strategy if responses are suboptimal or side effects are problematic. Your hematologist will review your response milestones and overall health to decide whether to continue, adjust or change treatment over time.